Acute sinusitis and sore throat in primary care

Del Mar, Chris

Published in:
Australian Prescriber

DOI:
10.18773/austprescr.2016.046

Published: 01/08/2016

Document Version:
Publisher's PDF, also known as Version of record

Link to publication in Bond University research repository.

Recommended citation (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator.
Acute sinusitis and sore throat in primary care

Chris Del Mar
Professor of Public Health Centre for Research in Evidence-Based Practice Faculty of Health Sciences and Medicine Bond University Gold Coast, Queensland

Keywords
acute sinusitis, antibiotic, sore throat symptom, tonsillitis


Introduction
Sore throat and acute sinusitis are both common reasons for consultations in Australian primary care. However, deciding how to manage affected patients is far from straightforward.

Diagnosis
Acute respiratory infections involve the respiratory mucosa that lines the pharynx and nasal passages, including sinuses and upper airway. Accurate diagnosis is clouded by a very wide spectrum of different sources of illness, and a vast array of microorganisms that are associated with, and may cause, infection. Many of these bacteria are normally present as commensals. We probably shed different types of virus far more often than we suffer symptoms of a viral infection. Symptoms can start at any mucosal site and go to any other – sniffles (nose), sore throat (tonsils or pharynx), acute cough (upper airway) and fever or malaise (systemic) – in any order (see Fig.).

Is the infection bacterial or viral?
Because the question of whether an infection is caused by bacteria or a virus underpins the conventional rational approach to management of infections, it has been the focus of much investigation. However, many studies of the microbiological environment of people with infection are difficult to interpret.

One of the organisms of greatest concern is group A beta-haemolytic streptococci. Historically, this infection has resulted in non-suppurative complications (acute rheumatic fever and glomerulonephritis), and secondary infections such as acute otitis media, sinusitis and quinsy. It is notoriously hard to predict from clinical signs, and culturing takes days, leaving only near-patient antigen testing as an option. Moreover, group A beta-haemolytic streptococci together with other organisms that cause respiratory infections (Neisseria meningitidis, Haemophilus, Chlamydia and Legionella) exist very commonly in people without symptoms.

Before focusing too closely on diagnosis, it is worth thinking about its purpose. How will treatment be influenced by diagnosis?

Treatment
The natural course of both sore throat and sinusitis is spontaneous resolution. Three questions should be asked:

• Do antibiotics reduce the severity or duration of symptoms?
• Do they reduce any complications?
• Do other interventions relieve symptoms?

These are necessary questions because of the spectre of antibiotic resistance – something that is approaching a catastrophe.

The evidence: antibiotics for acute sinusitis
In a Cochrane review investigating antibiotics for acute sinusitis, five studies randomised over 1000 patients to antibiotics or placebo. Analysis of the trials found there was a 0.66 risk ratio (95% CI* 0.47–0.94) if antibiotics were used, which

* CI confidence interval
means the relative risk of still having the illness at 1–2 weeks was 66% with antibiotics. Nevertheless, 86% of patients given placebo had recovered by 1–2 weeks anyway. This means that six out of every seven patients treated with antibiotics gained no benefit after 1–2 weeks, and by 16 to 60 days there was no difference in recovery and reports of complications between the antibiotic and placebo groups. The diagnostic inclusion criteria for the trials were rigorous with confirmation by X-ray or CT scan, or sinus puncture and aspiration. Clinical diagnosis was also more stringent than in normal clinical practice in Australia. The normal diagnostic spectrum of disease is much wider in general practice than in the trials, so the response to treatment would probably be less.

**The evidence: antibiotics for acute sore throat**

Another Cochrane review identified 15 trials (including 3621 participants) assessing antibiotics for acute sore throat. These trials reported on the incidence of symptoms three days after the patient had been seen by a clinician. (This is when the greatest benefit of antibiotics is evident.) In the control group, about 77% of patients were still experiencing throat soreness compared with 66% of patients given antibiotics (mostly penicillin). This represents a risk ratio of 0.68 (95% CI 0.59–0.79). The evidence is very robust (even a new well-conducted trial is unlikely to alter the summary effect substantively). The number of patients who need to be treated with antibiotics for one of them to benefit is 3.7 for those who have a positive throat swab for streptococci, 6.5 for those with a negative swab, and 14.4 for those not swabbed. It should be noted that trials that did not swab had a less serious case mix.

So if symptom control is not a good enough reason for using antibiotics, are there other reasons? Historically, sore throat has been of greater concern for its complications than its symptoms. Of these, acute rheumatic fever dominates. It is hard for us to appreciate now, 100 years later, the fear of ‘strep throat’ that used to frighten parents. An analysis of 16 trials of 10 101 patients found that 10 days of penicillin for sore throat was highly protective against acute rheumatic fever, with a risk ratio of 0.20 (95% CI 0.18–0.44). However, the trials are now more than 50 years old, and acute rheumatic fever has been disappearing steadily since the start of the 1900s. (The discovery of antibiotics in the mid-1900s makes no discernible blip on this downward trend.)

Now the risk of acute rheumatic fever is low – one case in every 10 GP-practising lifetimes – and is a weak justification for antibiotic use. In contrast, rural and remote indigenous communities of Australia experience acute rheumatic fever enough for antibiotic use for sore throat to be important.

**Harms from antibiotics**

Evidence is accumulating that antibiotics deliver common harms, including rashes, diarrhoea and thrush. However, data on adverse drug reactions are not comprehensive. If the infection is serious, these
Acute sinusitis and sore throat in primary care

common adverse reactions can be dismissed as trivial. However, if as in the case of antibiotics for sore throat and acute sinusitis, the benefits are marginal, antibiotic harms need to be factored in. GPs should discuss these harms, balanced against any benefits, with the patient before deciding on management.

Antibiotic resistance

There is also concern about antibiotic resistance. This is obvious for harm at the population level, but there is evidence that individuals carry antibiotic-resistant commensal bacteria for up to 12 months. The extent to which this compromises the effectiveness of antibiotics for subsequent potentially more serious infections has not been quantified.

Alternatives to antibiotics

Currently there are few effective alternatives to antibiotics in primary care. There is surprisingly little empirical evidence for the effectiveness of analgesics, and too little for other over-the-counter products (decongestants, several complementary and alternative medicines, caffeine) to recommend them. Steroids have been shown to be effective for acute sinusitis in four trials of 1943 patients. After 2–3 weeks, sinusitis resolved or improved in 73% of patients using intranasal steroids compared with 66% of those not using them, which means that 14 patients need to be treated for one to benefit.

REFERENCES


FURTHER READING